MedPath

Genetic response to Covid-19 infectio

Not Applicable
Conditions
Health Condition 1: U07-U07- Provisional assignment of new diseases of uncertain etiology or emergency use
Registration Number
CTRI/2021/10/037036
Lead Sponsor
Cancyte Technologies Private Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All patients who can read and understand English and given their informed consent

gave Informed Consent for the study

Covid-19 RT-PCR positive patients

Non-Vaccinated , Non-infected , asymptomatic and symptomatic volunteers - (Control Group)

Exclusion Criteria

Patient who have not given consent for this study

Pregnancy

People with the history of Cancer

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To identify immunological and inflammatory response of the host immune genes to Covid-19 infection.Timepoint: 2 Time points; Day 0 and Day 14
Secondary Outcome Measures
NameTimeMethod
To see the percentage change in immune and inflammatory gene panel selected for the study against controls.Timepoint: 2 Time points; Day 0 and Day 14
© Copyright 2025. All Rights Reserved by MedPath